NCT05121103View on ClinicalTrials.gov

A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Multiple Myeloma, RefractoryDiffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma RefractoryMultiple Myeloma in Relapse
Interventions
DRUG

EZM0414

Immediate-release film-coated tablets: Six dose levels starting at 100 mg, and then 200 mg, 300 mg, 400 mg, 600 mg, and 900 mg as well as an optional step-down dose level of 75 mg (if needed)

Trial Locations (8)

10021

Weill Cornell Medicine, New York

10029

Icahn School of Medicine at Mount Sinai, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

22031

NEXT Virginia, Fairfax

75246

Baylor University Medical Center (Texas Oncology), Dallas

77030

MD Anderson Cancer Center, Houston

91010

City of Hope, Duarte

08816

Astera Cancer Care, East Brunswick

Sponsors

Lead Sponsor

Epizyme, Inc.
All Listed Sponsors
lead

Epizyme, Inc.

INDUSTRY

NCT05121103 - A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma | Biotech Hunter | Biotech Hunter